3 completed, 3 unknown. 3 Phase 3, 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 2, Completed 1 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Radioimmunodetection: new trials by email Literature Review of Radioimmunodetection trials Research Report on Radioimmunodetection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis administration of Cimzia®, Immunoscintigraphy with radiolabeled Cimzia®. - Axial and Peripheral Spondyloarthritis, Rheumatoid Arthritis | Phase 3 | Completed | University Hospital, Ghent | 41 | 2012-10-18 | 2019-08-26 |
| DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements cholecalciferol, polymerase chain reaction, polymorphism analysis - Colorectal Cancer | Not applicable | Completed | Roswell Park Cancer Institute | 50 | 2007-08-01 | 2017-04-04 |
| Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer bevacizumab, pegfilgrastim, cyclophosphamide - Breast Cancer | Not applicable | Unknown | Memorial Sloan Kettering Cancer Center | 75 | 2006-07-01 | 2014-01-06 |
| Proteases in Patients With Prostate Cancer That Has Spread to the Bone fluorescence in situ hybridization, microarray analysis, molecular diagnostic method - Anemia, Metastatic Cancer | Completed | Barbara Ann Karmanos Cancer Institute | 31 | 2001-07-01 | 2014-02-11 | |
| Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma immunoscintigraphy, technetium Tc 99m epratuzumab - Lymphoma | Phase 2 / Phase 3 | Unknown | Gilead Sciences | 60 | 1997-03-01 | 2021-08-16 |
| Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma immunoscintigraphy, technetium Tc 99m epratuzumab - Lymphoma | Phase 3 | Unknown | Gilead Sciences | 100 | 1997-03-01 | 2021-08-16 |
Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia (1) · Arthritis, Rheumatoid (1) · Breast Neoplasms (1) · Breast Neoplasms, Male (1) · Colonic Neoplasms (1)
Gilead Sciences (2) · Barbara Ann Karmanos Cancer Institute (1) · Memorial Sloan Kettering Cancer Center (1) · Roswell Park Cancer Institute (1) · University Hospital, Ghent (1)
United States (5) · Austria (2) · Italy (2) · Sweden (2) · Switzerland (2) · Belgium (1)
William A. Wegener, MD, PhD (2) · Filip Van den Bosch, MD (1) · Marwan Fakih, MD (1) · Maura N. Dickler, MD (1) · Michael L. Cher, MD (1)
2009 (1), P30CA022453 (1)